

Filed Electronically

<b>PETITION FOR CERTIFICATE OF CORRECTION</b>  Address to: Mail Stop Certificate of Correction Branch Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Attorney Docket	STAN-201
	First Named Inventor	CRABTREE, GERALD R.
	Patent Number	7,323,439
	Issue Date	January 29, 2008
	Application Number	09/960,708
	Filing Date	September 19, 2001
Title: <i>"METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS"</i>		

Sir:

Transmitted herewith for filing is a Certificate of Correction for the above-identified patent. Please correct the following:

**In The Claims:**

- Claim 1 line 42: Delete "anglogenesis" and replace it with "angiogenesis".
- Claim 17 line 41: Delete "Said" and replace it with "said".

Attached herewith is a copy of the corresponding pages of the last amendment as filed October 12, 2005 to support our request for correction.

It is believed that no fee is due since the error was made by the Patent and Trademark Office. However, the Commissioner is hereby authorized to charge any fees under 37 C.F.R. § 1.20, which may be required by this paper, or to credit any overpayment, to Deposit Account No. 50-0815 order number STAN-201.

Respectfully submitted,

BOZICEVIC, FIELD & FRANCIS LLP

Date: April 15, 2008

By: /David C. Scherer, Reg.#56993/  
David C. Scherer  
Registration No. 56,993

BOZICEVIC, FIELD & FRANCIS LLP  
1900 University Avenue, Suite 200  
East Palo Alto, California 94303  
Telephone: (650) 327-3400  
Fax: (650) 327-3231

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. (Also Form PTO-1050) If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 7,323,439  
APPLICATION NO.: 09/960,708  
ISSUE DATE : January 29, 2008  
INVENTOR(S) : CRABTREE, GERALD R.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

### In The Claims:

- Claim 1 line 42: Delete "anglogenesis" and replace it with "angiogenesis".
- Claim 17 line 41: Delete "Said" and replace it with "said".

MAILING ADDRESS OF SENDER (Please do not use customer number below):

**BOZICEVIC, FIELD & FRANCIS LLP**  
1900 University Avenue, Suite 200  
East Palo Alto, California 94303

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

LISTING OF CLAIMS

Below is a listing of the claims pending in the subject application. No amendments are made in this response.

Claims:

- 1-7. (Canceled)
8. (Previously Presented) A method of inhibiting angiogenesis/vascular development in a host having a condition associated with unwanted angiogenesis, said method comprising:  
systemically administering to said host an effective amount of a Ca<sup>2+</sup>/calcineurin/NF-ATc inhibitory agent to inhibit angiogenesis/vascular development in said host having a condition associated with unwanted angiogenesis.
9. (Original) The method according to Claim 8, wherein said agent is an NF-ATc antagonist.
10. (Original) The method according to Claim 9, wherein said agent inhibits phosphorylation of NF-ATc.
11. (Original) The method according to Claim 10, wherein said agent inhibits NF-ATc phosphorylation by binding to calcineurin.
- 12-14. (Canceled)
15. (Previously Presented) A method of inhibiting tumor growth in a host having a neoplastic disease condition, said method comprising:  
systemically administering to said host having a neoplastic disease condition an effective amount of a Ca<sup>2+</sup>/calcineurin/NF-ATc inhibitory agent to inhibit tumor

41. (Previously Presented) The method according to Claim 15, wherein said agent is rapamycin or a synthetic mimetic thereof.

42. (Previously Presented) The method according to Claim 15, wherein said agent is a cyclosporin.

43. (Previously Presented) The method according to Claim 42, wherein said cyclosporin is cyclosporin A.

44. (Previously Presented) The method according to Claim 42, wherein said cyclosporin is a synthetic derivative or mimetic of cyclosporin A.

45. (Canceled)

46. (Previously Presented) A method of inhibiting angiogenesis/vascular development in a host having a condition associated with unwanted angiogenesis, said method comprising:

administering to said host an effective amount of a cyclosporin to inhibit angiogenesis/vascular development in a host having a condition associated with unwanted angiogenesis.

47. (Previously Presented) A method of inhibiting tumor growth in a host having a neoplastic disease condition, said method comprising:

administering to said host an effective amount of a cyclosporin to inhibit tumor growth in said host having a neoplastic disease condition.